Medical Condition

lymphoma

Total Trials

32

Recruiting Now

32

Trial Phases

Phase 3, Phase 1, Phase 2

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas — each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — lymphoma Clinical Trials

How many clinical trials are currently recruiting for lymphoma?

ClinicalMetric currently tracks 32 actively recruiting clinical trials for lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 32. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for lymphoma?

lymphoma research spans Phase 1 (7 trials), Phase 2 (9 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a lymphoma clinical trial?

Eligibility criteria for lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

National Cancer Institute (NCI) 3 trials

UNC Lineberger Comprehensive Cancer Center 2 trials

Memorial Sloan Kettering Cancer Center 2 trials

Second Affiliated Hospital, School of Medicine, Zhejiang University 1 trial

SecuraBio 1 trial

lymphoma

Frequently Asked Questions — lymphoma Clinical Trials

Recruiting Clinical Trials

AI-assisted Diagnosis of Malignant Brain Tumors

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma

A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

Digital Peer Navigation for Adolescents and Young Adults With Cancer

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

Clinical Cohort of Lymphoma Patients in Malawi

A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Effects of Exercise Training in Survivors of Lymphoma

Remote Monitoring and Symptom Management Digital Application

Mediastinal EBUS Cryobiopsy Study In Sweden

Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma

Italian Study of Patients With Lymphoma

A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Danish Elder Lymphoma Patient Hematopoietic Investigation

Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation.

xDRIVE for Florida-based Cancer Patients

Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)

Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies